clinical trial · NCT02711553
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Eli Lilly and Company·phase2·active not recruiting·n = 309
Biliary Tract CancerMetastatic CancerAdvanced CancerRamucirumabMerestinibCisplatinGemcitabinePlacebo OralPlacebo IV
brief summary
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
started
May 19, 2016
primary completion
Feb 16, 2018
completion
Dec 1, 2026
last updated
Jul 22, 2026
official title
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol